Why you should be investing in Cannabis (Part 1) Posted on April 23, 2019 (April 27, 2019) by Michael Munoz Even though the global Cannabis market is still in its infancy, many investment experts are making bold predictions about where it could be headed, such as The Green Fund’s Mark Bernberg who wrote recently “We believe that the largest cannabis company in the world doesn’t even exist yet.” Value as a Medicine Cannabis is one of the fastest growing industries in the world. As the liberalization of Cannabis laws continues, and access to medicinal products derived from Cannabis increases the value of medical cannabis institutions and products are expected to increase accordingly. Some estimates predict that the value of the North American Cannabis market will reach 146.4 billion dollars by the end of 2025 (1). A significant contributor to that forecasted growth is the increased use of Cannabis derived medicines and treatments for a broader range of ailments and conditions than it is currently being used to care for. Due to recent regulatory changes medical professionals, researchers, and scientists will have more opportunities to study the effects of Cannabinoid compounds. This will likely lead to the discovery of better and more varied ways to employ Cannabis as a medicine. In a related development, on March 20th of this year, Mr. Glenn E. Martin, CEO of WEED, Inc. announced that WEED, Inc., and Yissum (of the Hebrew University of Jerusalem) signed first-of-its-kind deal for exclusive license, assignment and transfer to WEED Inc. of groundbreaking intellectual property for novel technologies and formulations of cannabis-related and cannabinoid-based products for the treatment of medical disorders and conditions. WEED Inc. in the same press release also announced that it has entered into a consulting agreement with Prof. Elka Touitou, of the Institute of Drug Research, School of Pharmacy, The Hebrew University of Jerusalem. Prof. Touitou is a pioneer in cannabinoid research and published the firsts scientific work on transdermal delivery of cannabinoids in 1988. Prof. Touitou and WEED, Inc. are looking to develop efficient products focused on woman’s health, utilizing Cannabinoids.